




# Serotonin Club Newsletter



## Program for Japan has been set!!

The next meeting of the Serotonin Club will be in Sapporo Japan. The meeting is being organized locally by Dr. Mitsuhiro Yoshioka and Tsukasa Koyama who have already obtained the venue and nearby hotels.

**June 27-30, 2006**  
**Hokkaido University**  
**Sapporo, Japan**

Page Lecture to be given by John Harvey

Rapport Lecture to be given by Richard Green

## The program includes sixteen symposia:

- Mood Disorders and Serotonin: New Clinical Aspects
- The 5-HT<sub>3</sub> Receptor: From Structure to Function
- What Serotonin Does in the Cerebral Cortex: An Update
- The Impact of the 5-HT System on Immune Cells
- Recent Developments in the Medicinal Chemistry and Biology of 5-HT<sub>7</sub> and 5HT<sub>5A</sub> Receptors
- 5-HT Receptors Mediating Cardiovascular Responses: Therapeutic Implications
- Serotonergic Regulation of the Mammalian Circadian Clock
- Anatomical and Physiological Diversity of Midbrain Serotonin Neurons
- Serotonin and Brain-derived Neurotrophic Factor: A Dynamic Duo in Determining Brain Function and Behavior
- Update on 5-HT Receptors as Molecular Targets for Obesity
- 5HT<sub>6</sub> Antagonists: New Drugs for Old Diseases
- 5-HT Receptor Interacting Proteins and Signal Transduction
- Defining the Link Between Serotonin, Stress, Depression, and Neuronal Plasticity
- Serotonin in the Gut and its Relevance to Human Disease
- Treatments for Cognitive Deficits in Schizophrenia
- Human Psychopharmacology of Serotonin Receptors

Meeting registration and poster abstract submission will begin in December with a deadline in February. Watch the Serotonin Club website and your email for forthcoming deadlines!!!

The organizing committee is working on obtaining funding to support students and speakers. Please help in any way you can. If you think you may be able to obtain funding from your organization please contact one of the councilors.

## **Serotonin Club Dinner Society for Neuroscience 2005**

The Serotonin Club dinner will be held at the Marrakesh restaurant on Monday November 14<sup>th</sup> from 6:30 to 10:00 pm. This is a purely social event with no speeches. Eat, drink network, bring your students, postdocs, friends, mentors. You do not have to be a member of the Serotonin Club to come to the dinner. The Marrakesh is located near the convention center at 617 New York Ave, NW. The Marrakesh is a premier authentic Moroccan restaurant. Contact Sheryl Beck if you would like to attend. Rich tapestries surround you and the rhythms of Moroccan music fill the air. Belly dancing is optional!!

## **Future Meetings**

Society for Neuroscience, Wash. D.C., Nov. 12-16  
ACNP, Kona Hawaii, December 11-15  
British Pharmacological Society, December 20-22  
WCBR Steamboat Springs, CO, Jan 21-27  
FASEB, San Francisco, April 1-6, 2006  
IUPHAR, Beijing China July 2-7 2006

## **IUPHAR Serotonin Receptor Nomenclature Committee**

Graeme Martin, the chair of the NC-IUPHAR subcommittee on Serotonin Receptors, is soliciting nominations for people interested in serving on the nomenclature committee. Also, keep in mind that work is in progress on revising the serotonin receptor compendium. If interested please contact Graeme at [Graeme.martin@discovery-insight.com](mailto:Graeme.martin@discovery-insight.com). For more information you may visit the NC-IUPHAR website <http://www.iuphar.org/nciuphar.html> or for the 5-HT receptor page <http://www.iuphar-db.org/iuphar-rd/query?type=link&IType=chapter&id=1288>.

## **Pay your dues using**



Go to [serotoninclub.org](http://serotoninclub.org) website for instructions. If you are receiving this newsletter then you are already a member. We will contact you when it is time to renew. **PLEASE URGE YOUR COLLEAGUES TO JOIN!!!!**  
**You may also send a check for \$60 US payable to the Serotonin Club directly to Sheryl Beck.**

## **Awards**

Richard Green, former secretary/treasurer of the Serotonin club, has recently been appointed Special Professor of Neuropharmacology at the University of Nottingham.  
The Paton Memorial Lecture to be given at the Winter meeting of the British Pharmacological Society (December 20-22, 2005) by Dr. John Fozard (Novartis, Switzerland) entitled: From Cocaine to Chemotherapy: The Discovery and Therapeutic Exploitation of Selective 5-HT<sub>3</sub> Receptor Antagonists". Dr. Fozard will also be appointed an honorary fellow of the British Pharmacological Society.

## Timeless Pharmacology: A Celebration to honor the retirement of John R. Fozard, Ph.D.



U Quast, C Page, D Hoyer, M Goethert, T Blackburn, A Weston, PPA Humphrey, J Fozard, M Spedding, B Richardson, P Saxena, S Holgate, H Rang, M Blackburn, M Moskowitz, J Westwick, and G Burnstock

The symposium that took place in Horsham to celebrate John's achievements was highly successful and provided ample opportunities for old and new friends (of which a number are members of the Club as can be seen from program and the picture) to meet. Besides being a friend a mentor to many of us in the 5-HT field, John was also instrumental in providing a solid basis for the Serotonin Club's finances. Indeed, the 2<sup>nd</sup> IUPHAR satellite meeting on Serotonin in Basel in 1990, organized by John and Pramod Saxena, another distinguished member of the club, was such a success that we were able to seed quite some money into the club's accounts. This was first cautiously managed by Danny Hoyer and Ewan Mylecharane, and then very professionally by Richard Green, making possible the organization of a number of excellent meetings under the club's auspices, also allowing students to attend these meetings at low cost and/or with substantial travel grants. The program of the symposium and John's CV both illustrate that John is a man of many interests and a true friend indeed.

## A symposium to mark the retirement of John R. Fozard Novartis Institutes for BioMedical Research,

Session 1: Chairperson: **Pramod Saxena**  
**Patrick Humphrey.**

Receptors, Agonists and Headaches

**Michael Moskowitz.**

Migraine Mechanisms: Novel Approaches, Novel Treatments

**Daniel Hoyer.**

A Brain-Wide Approach to Target Validation using RNA Interference and Behavioural Readouts.

Session 2: Chairperson: **Humphrey Rang**

**Manfred Goethert.**

Allosteric Modulation of 5-HT<sub>3</sub> Receptors by Cannabinoids: Evidence in vitro and Relevance in vivo

**Arthur Weston.**

The Secret Life of an Old Friend: Is the Vascular Endothelium an Ion Sensor?

**Ulrich Quast.**

ATP-Sensitive Potassium Channels as Drug Targets

Session 3:

Chairperson: **Brian Richardson.**

**Geoffrey Burnstock.**

Purinergic Signaling: Therapeutic Potential

**Bertil Fredholm.**

Targeting Adenosine Receptors

**Michael Blackburn.**

Regulation of Endogenous Adenosine; Insights into Adenosine Signaling in Pulmonary Inflammation and Remodeling

Session 4: Chairperson: **John Westwick.**

**Stephen Holgate.**

Adenosine: A New Therapeutic Target in Asthma

**Clive Page.**

Heparin: an Endogenous Anti-inflammatory Agent - Implications for Treatment of Inflammatory Diseases

**John Fozard.**

Veterinary Misalliance and Other Missed Opportunities  
Close: **John Westwick**

John Fozard obtained a degree in Pharmacy from the University of London in 1963 and a PhD in Pharmacology from the University of Bradford in 1968. From 1965 to 1977, he was Lecturer then Senior Lecturer in Pharmacology at the University of Manchester. In 1970 - 1971, he spent a sabbatical year with Professor Erich Muscholl in the Department of Pharmacology of the University of Mainz

working on presynaptic cholinergic receptors. In 1977, he moved from Manchester to be Head of Pharmacology at the Merrell Dow Research Institute in Strasbourg. In 1987 he joined Sandoz, Basel, as Head of Hypertension Research and was Head of Asthma Research from 1993-1996. From 1996 to 1999 he was Head of Respiratory Disease Research at Novartis with the primary responsibility of building up a new Respiratory Disease Research Centre in Horsham. He last was a Novartis Distinguished Scientist in the Respiratory Disease research section of the Novartis Institutes for Biomedical Research. His scientific achievements include the definition of the essential role of putrescine in early mammalian embryogenesis (publication in Science, nominated for the AAAS Newcomb Cleveland Prize), the identification of 8-hydroxy-2-(di-n-propylamino)-tetralin as a selective 5-HT<sub>1A</sub> receptor agonist (8th most cited paper in the xenobiotics literature, 1981 - 1992) and the first demonstration of the powerful regional vasodilator effects of endothelin, "the most powerful vasoconstrictor yet described" (selected as a "Hot Paper" by The Scientist). John Fozard discovered the first potent and selective antagonist at 5-HT<sub>3</sub> receptors (MDL 72222) which was used in proof-of-concept studies to provide support for a novel theory of the pain of migraine. He also identified a follow-up, MDL 73147 (dolasetron), which is marketed as Anzemet. His laboratory has provided key data to support the clinical testing of many development compounds including eflornithine (ornithine decarboxylase inhibitor), WAG994 (adenosine A1 receptor agonist), KCO912 (airways-selective KATP channel opener), DNK333 (NK1/NK2 receptor antagonist) QAF805 (adenosine A2B/A3 receptor antagonist) and QAB149 (long acting beta adrenoceptor agonist). He gave the 'Ariens Lecture' to the Dutch Pharmacological Society in 1986 and the 'Kenneth Brizzee Lecture' at Emesis '92. He was the British

Pharmacological Society Australasian visitor in 1986. In 1992, he was designated Fellow of the Royal Pharmaceutical Society of Great Britain for "Distinction in the Science of Pharmacy" and in 2005 was elected a Fellow of The British Pharmacological Society for "Distinction in Pharmacology through Scholarship and Service to the Society". He is currently an executive editor of Pharmacology and Therapeutics, an editor of Naunyn-Schmiedeberg's Archives of Pharmacology and British Journal of Pharmacology and is an editorial board member of several other journals including Trends in Pharmacological Sciences. John Fozard has published over 210 original research and review papers and according to the Institute of Scientific Information was ranked the 26th most cited scientist in Pharmacology and Toxicology covering the period 1993-2003. At the Winter meeting of the BPS, John will give the Paton lecture. (Thanks to Dan Hoyer for submitting the information regarding Dr. Fozard)

Sheryl G. Beck (Secretary/Treasurer)  
ARC room 402A

Children's Hospital of Philadelphia  
Philadelphia, PA 19104-4318

[becks@email.chop.edu](mailto:becks@email.chop.edu) or [beck5ht@comcast.net](mailto:beck5ht@comcast.net)

tel: 215-590-0651

Donna O'Brien (Administrative Assistant)

Tel: 215-590-3381